Baxter International Faces Class Action Amid Concerns
Investors who acquired securities in Baxter International, Inc. (NYSE: BAX) should take note of serious developments surrounding the company. In recent months, concerns have grown about the safety of Baxter's Novum IQ Large Volume Pump (Novum LVP), resulting in a class action lawsuit.
Understanding the Safety Concerns
On April 7, 2025, unsettling reports emerged regarding Baxter's Novum LVP, a crucial device used to deliver fluids, medications, and nutrients intravenously to patients. These concerns were triggered by a whistleblower report from a Missouri news outlet that highlighted significant issues regarding the pump's accuracy in infusion, causing alarm among users.
Timeline of Events
Just weeks after the initial reports, Baxter sent out a warning letter to its customers on April 24, 2025, acknowledging underinfusion risks associated with the Novum LVP. The letter mentioned only one serious injury linked to this device, but that was merely the tip of the iceberg. Following further incidents, on July 14, 2025, the company reiterated the risks related to overinfusion, citing 79 reports of serious injuries and even two patient deaths connected to the device.
On July 31, 2025, Baxter's announcement to voluntarily halt all shipments and planned installations of the pump shocked investors. The news caused the value of Baxter shares to plummet significantly—down $6.29, or roughly 22.4%, from $28.05 to $21.76.
What Is The Lawsuit About?
The class action lawsuit has been initiated on behalf of investors who bought securities in the company between February 23, 2022, and July 30, 2025. The core allegations assert that Baxter misled its investors by failing to disclose crucial information about the systemic defects of the Novum LVP. These defects resulted in widespread malfunctions, which posed serious health risks to patients.
Key Allegations in the Lawsuit
The lawsuit specifically points to Baxter's failure to inform investors that:
- Systemic defects in the Novum LVP led to malfunctions such as underinfusion and overinfusion, which could endanger patients.
- The company had received numerous complaints related to device malfunctions, injuries, and patient fatalities.
- Baxter's remedial actions to address these serious defects were deemed inadequate and failed to resolve the underlying issues effectively.
- The risk existed that customers would be advised to retire existing Novum LVP devices from service due to these persistent problems, ultimately leading to a complete pause in new sales.
Investor Options
If you've experienced financial loss from your investments in Baxter, it's imperative to act quickly. Investors have until December 15, 2025, to request lead plaintiff appointment in this class action suit. Engaging with legal counsel could provide valuable insights into your rights and options.
Getting Legal Advice
For those interested in discussing their legal rights, Kirby McInerney LLP offers free consultations. Interested parties should reach out via email at investigations@kmllp.com or visit their contact page.
About Kirby McInerney LLP
Kirby McInerney LLP, based in New York, specializes in securities, antitrust, and consumer litigation. The firm has a proven track record, recovering billions for shareholders through litigation. For more details, visit their official website.
Frequently Asked Questions
What safety issues are associated with Baxter's Novum LVP?
The Novum LVP has been linked to serious safety concerns, including risks of underinfusion and overinfusion, which can pose grave dangers to patients.
What is the timeline for the class action lawsuit?
Investors have a deadline of December 15, 2025, to request lead plaintiff appointment for the class action against Baxter.
How can investors contact Kirby McInerney LLP?
Investors can reach out to Kirby McInerney LLP via email at investigations@kmllp.com or through their website.
What are the key allegations of the lawsuit?
The lawsuit alleges that Baxter misled investors by failing to disclose the systemic defects and safety risks of the Novum LVP.
How has Baxter's stock price been affected by these concerns?
Following the announcement of safety concerns and recalls, Baxter's stock price fell significantly by approximately 22.4%.
